Pharmacokinetics
| Parameter . | n . | Geometric mean . | 95% CI . |
|---|---|---|---|
| Half-life (h) | 19 | 3.04* | 2.30-3.78 |
| Cmax (ng/mL)† | 36 | 427.0 | 342.4-511.5 |
| AUClast (hr·ng/mL) | 36 | 1498 | 937.2-2058 |
| AUCinf (hr·ng/mL) | 19 | 1899 | 1293-2505 |
| Vzobs (L/m2) | 19 | 19.01 | 13.55-24.47 |
| Clobs (L/hr/m2)‡ | 19 | 7.37 | 4.96-9.77 |
| Parameter . | n . | Geometric mean . | 95% CI . |
|---|---|---|---|
| Half-life (h) | 19 | 3.04* | 2.30-3.78 |
| Cmax (ng/mL)† | 36 | 427.0 | 342.4-511.5 |
| AUClast (hr·ng/mL) | 36 | 1498 | 937.2-2058 |
| AUCinf (hr·ng/mL) | 19 | 1899 | 1293-2505 |
| Vzobs (L/m2) | 19 | 19.01 | 13.55-24.47 |
| Clobs (L/hr/m2)‡ | 19 | 7.37 | 4.96-9.77 |
Cmax indicates maximum plasma concentration; AUClast, area under the curve from time zero to time of final quantifiable sample; AUCinf, area under the curve extrapolated to infinity; Vz, volume of distribution during the terminal phase; and Cl, systemic clearance.
Pharmacokinetic analysis was not possible in ten patients, and a full analysis was not possible in 17 patients. One patient was excluded from this table due to receiving a dose of 18 mg/m2.
The median half-life was 3.14 h (range: 1.04-6.77).
Cmax is reported as observed value.
Clearance is expressed as L/hr/m2 due to the BSA dosing employed.